Relevant bibliographies by topics / Parkinson´s disease - Physical symptoms / Journal articles
To see the other types of publications on this topic, follow the link: Parkinson´s disease - Physical symptoms.

Journal articles on the topic 'Parkinson´s disease - Physical symptoms'

Author: Grafiati
Published: 4 June 2021
Last updated: 19 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Parkinson´s disease - Physical symptoms.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Belash, V. O., A. M. Batenina, and A. I. Machulina. "Possibility of osteopathic correction in the complex therapy of patients with Parkinson′s disease." Russian Osteopathic Journal, no. 2 (July 3, 2021): 19–30. http://dx.doi.org/10.32885/2220-0975-2021-2-19-30.

Full text
Abstract:
Introduction. Parkinson′s disease (PD) is a slowly progressive chronic disease and currently all available treatments are aimed at alleviating the symptoms of the disease and improving the quality of patients′ life. The main correction is drug therapy. Taking into account the progressive nature of the disease, the insuffi cient effectiveness of drug therapy, as well as early and frequent complications from drug therapy, the search for new pathogenetic and symptomatic drugs, as well as additional non-drug methods of treatment, is constantly being conducted. A number of authors have also previously demonstrated positive changes in the state of motor functions and regression of some neurological manifestations in PD patients with the use of certain osteopathic correction techniques. The above suggests that osteopathic correction may become one of the new directions in the treatment of PD within the framework of complex therapy.The aim of the study is to substantiate the possibility of the inclusion of osteopathic correction of patients with Parkinson′s disease in complex therapy.Materials and methods. A controlled, randomized prospective study was carried out at the Bakhrushin Brothers City Clinical Hospital and the «Ear, Throat and Nose Clinic» (Moscow) medical center from April 2019 to January 2020. The study included 24 patients aged 60 to 78 years with a diagnosis of Parkinson′s disease stage I–II according to Hoehn and Yahr. Depending on the applied treatment method, the patients were divided by simple randomization into two comparable groups (main and control) of 12 people each. All observed patients received common drug therapy and exercise therapy. Additionally, the patients of the main group underwent osteopathic correction (within 3 months, once every 14 days, a total of 6 sessions were performed). All patients, regardless of the group, underwent an osteopathic examination before and after treatment, with the formulation of an osteopathic conclusion; the quality of life was assessed according to the Medical Outcomes Study 36-Item Short-Form Health Survey, and the impact of motor and non-motor symptoms of PD on the daily activity of patients was assessed using the unifi ed PD assessment scale of the International Society of Movement Disorders (MDS UPDRS).Results. The use of osteopathic correction together with drug therapy in PD patients leads to a statistically signifi cant (p<0,05) improvement in quality of life indicators (vitality scale and physical health scale) and daily physical activity (depression level). There is also a change in the structure of the dominant somatic dysfunctions (SD) in the form of a signifi cant decrease in the number of global SD.Conclusion. To increase the effectiveness of complex therapy for patients with PD, the common drug therapy can be supplemented with osteopathic methods of correction.
APA, Harvard, Vancouver, ISO, and other styles
2

Bohnen, Nicolaas I., Roger L. Albin, Martijn LTM Müller, and Kelvin L. Chou. "Advances in Therapeutic Options for Gait and Balance in Parkinson’s Disease." US Neurology 07, no. 02 (2011): 100. http://dx.doi.org/10.17925/usn.2011.07.02.100.

Full text
Abstract:
There is a need to explore non-dopaminergic approaches to treating balance and gait problems in Parkinson’s disease (PD). There is emerging evidence on the role of cholinergic denervation of the pedunculopontine nucleus (PPN) thalamus system and falls in PD. Preliminary clinical trial data suggest that the subgroup of PD patients with frequent falls may be suitable candidates for future cholinergic augmentation clinical trials. Recent controlled clinical trials using methylphenidate have been unable to confirm earlier reports of improved gait in PD. Although progressive deterioration of axial motor symptoms occur with deep brain stimulation of the subthalamic nucleus or globus pallidus interna, new preliminary research suggests that other surgical stimulation sites, such as the PPN, may have a potential benefit on gait and balance impairments in PD. Continuing vigorous exercise and physical fitness should be highly encouraged to patients with PD who are at risk of physical deconditioning and fear of falling, but effective antifall physical therapy interventions remain an unmet clinical need.
APA, Harvard, Vancouver, ISO, and other styles
3

Cotterell, Phil, Debbie Weight, Sharon Joseph, and Paul Joseph. "Complex Parkinson's disease: review and experiences." British Journal of Healthcare Assistants 13, no. 8 (August 2, 2019): 394–400. http://dx.doi.org/10.12968/bjha.2019.13.8.394.

Full text
Abstract:
The rate of Parkinson's disease progression is highly individual. It is important to identify those in the complex stage of the disease. Non-oral therapies may be appropriate for those in the complex stage of the disease who experience motor fluctuations, but there can be reasons for a failure to explore these options. Complex Parkinson's disease is a challenging time for the patient, their carer/s and for Parkinson's specialists. Changes to independence can be difficult to deal with, and the disease has an impact both physically and psychologically. For carers, the impact of Parkinson's can also result in physical and psychological issues, as well as social and financial problems. Consideration often turns to moving into a care environment, dealing with neuropsychiatric issues and challenging unmet need. Dealing with symptoms and problems using a team and a palliative approach is required.
APA, Harvard, Vancouver, ISO, and other styles
4

Cotterell, Phil, Debbie Weight, Sharon Joseph, and Paul Joseph. "Complex Parkinson's disease: review and experiences." British Journal of Neuroscience Nursing 15, no. 3 (June 2, 2019): 140–45. http://dx.doi.org/10.12968/bjnn.2019.15.3.140.

Full text
Abstract:
The rate of Parkinson's disease progression is highly individual. It is important to identify those in the complex stage of the disease. Non-oral therapies may be appropriate for those in the complex stage of the disease who experience motor fluctuations, but there can be reasons for a failure to explore these options. Complex Parkinson's disease is a challenging time for the patient, their carer/s and for Parkinson's specialists. Changes to independence can be difficult to deal with, and the disease has an impact both physically and psychologically. For carers, the impact of Parkinson's can also result in physical and psychological issues as well as social and financial problems. Consideration often turns to moving into a care environment, dealing with neuropsychiatric issues and challenging unmet need. Dealing with symptoms and problems using a team and a palliative approach is required.
APA, Harvard, Vancouver, ISO, and other styles
5

Fiorilli, Giovanni, Federico Quinzi, Andrea Buonsenso, Giusy Casazza, Luigi Manni, Attilio Parisi, Alfonso Di Costanzo, Giuseppe Calcagno, Marzia Soligo, and Alessandra di Cagno. "A Single Session of Whole-Body Electromyostimulation Increases Muscle Strength, Endurance and proNGF in Early Parkinson Patients." International Journal of Environmental Research and Public Health 18, no. 10 (May 20, 2021): 5499. http://dx.doi.org/10.3390/ijerph18105499.

Full text
Abstract:
Parkinson’s disease (PD) patients lead a sedentary lifestyle, being unable or unwilling to exercise conventionally, due to physical and mental limitations. The aim of this study was to assess the acute effects of a single session of whole-body electromyostimulation (WB-EMS) on the physical performances and serum levels of the neurotrophic factors in PD patients. Ten subjects (aged 72.60 ± 6.82) underwent 20 min of physical activity with superimposed WB-EMS and, after four weeks, the same protocol with no WB-EMS. WB-EMS was conducted with intermittent stimulation, with 4 s WB-EMS/4 s rest, at 85 Hz, 350 μs. A physical fitness assessment and blood samples collection, to evaluate neurotrophic factors’ levels (BDNF, FGF21, proNGF, mNGF), were collected before and after the intervention. The RM-ANOVA showed significant improvements in sit-to-stand (p < 0.01), arm curl (p < 0.01), handgrip (p < 0.01) and soda pop test (p < 0.01) after the WB-EMS intervention. Higher proNFG serum levels were observed in the WB-EMS condition compared to the no WB-EMS after 60 min post-intervention (p = 0.0163). The effect of WB-EMS confirmed the electrostimulation ability to modulate the proNGF quantity. The positive impact of the WB-EMS protocol on physical functioning, and eye–hand coordination, makes this intervention a promising strategy to improve motor and non-motor symptoms in PD patients.
APA, Harvard, Vancouver, ISO, and other styles
6

Church, Frank C. "Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease." Biomolecules 11, no. 4 (April 20, 2021): 612. http://dx.doi.org/10.3390/biom11040612.

Full text
Abstract:
Parkinson’s disease (PD) usually presents in older adults and typically has both motor and non-motor dysfunctions. PD is a progressive neurodegenerative disorder resulting from dopaminergic neuronal cell loss in the mid-brain substantia nigra pars compacta region. Outlined here is an integrative medicine and health strategy that highlights five treatment options for people with Parkinson’s (PwP): rehabilitate, therapy, restorative, maintenance, and surgery. Rehabilitating begins following the diagnosis and throughout any additional treatment processes, especially vis-à-vis consulting with physical, occupational, and/or speech pathology therapist(s). Therapy uses daily administration of either the dopamine precursor levodopa (with carbidopa) or a dopamine agonist, compounds that preserve residual dopamine, and other specific motor/non-motor-related compounds. Restorative uses strenuous aerobic exercise programs that can be neuroprotective. Maintenance uses complementary and alternative medicine substances that potentially support and protect the brain microenvironment. Finally, surgery, including deep brain stimulation, is pursued when PwP fail to respond positively to other treatment options. There is currently no cure for PD. In conclusion, the best strategy for treating PD is to hope to slow disorder progression and strive to achieve stability with neuroprotection. The ultimate goal of any management program is to improve the quality-of-life for a person with Parkinson’s disease.
APA, Harvard, Vancouver, ISO, and other styles
7

Del Felice, Alessandra, Leonora Castiglia, Emanuela Formaggio, Manuela Cattelan, Bruno Scarpa, Paolo Manganotti, Elena Tenconi, and Stefano Masiero. "P73-S TACS and physical therapy for motor and cognitive symptoms in Parkinson’s disease: randomized cross-over trial." Clinical Neurophysiology 130, no. 7 (July 2019): e114. http://dx.doi.org/10.1016/j.clinph.2019.04.601.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ferreira, Rodrigo N., Aline S. de Miranda, Natalia P. Rocha, Ana C. Simoes e Silva, Antonio L. Teixeira, and Elizabeth R. da Silva Camargos. "Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?" Current Medicinal Chemistry 25, no. 31 (October 16, 2018): 3682–702. http://dx.doi.org/10.2174/0929867325666180313101536.

Full text
Abstract:
Background: Parkinson´s Disease (PD) is a chronic, progressive condition, being the second most common neurodegenerative disorder worldwide. The classical features include: bradykinesia, resting tremor, rigidity and festination. These neurological alterations are probably due to the death of dopaminergic neurons in the Substantia Nigra pars compacta and consequent reduction of dopamine input into the striatum. The decrease of dopamine levels may also be involved in the emergence of non-motor symptoms, including cognitive impairment, anxiety and depression symptoms. Neurotrophic Factors (NF) are proteins that modulate neuronal function, development, and survival. It has been reported that NF might exert a protective role in PD. Objective: We aim to discuss the emerging evidence from pre-clinical and clinical studies regarding the role of NF in PD as well as their potential as promising therapeutic strategies. Methods: We carried out an extensive literature search in PubMed central. Results: Pre-clinical studies using NF to treat PD are divergent probably due to several methodological differences, thus precluding any conclusion. Clinical studies findings obtained with the administration of NF in patients with PD were even more disappointed. On the other hand, pre-clinical and clinical studies generally support that physical activity is a low-cost, non-pharmacologic strategy with good results to treat PD. Conclusion: The use of NF as a treatment for PD is still a promise not incorporated in clinical practice. Methods to deliver NFs, doses and compounds administered, side effects, population characteristics and duration of disease may probably contribute to the unsuccessful results.
APA, Harvard, Vancouver, ISO, and other styles
9

Wasiuk-Zowada, Dagmara, Andrzej Knapik, Justyna Szefler-Derela, Anna Brzęk, and Ewa Krzystanek. "Kinesiophobia in Stroke Patients, Multiple Sclerosis and Parkinson’s Disesase." Diagnostics 11, no. 5 (April 28, 2021): 796. http://dx.doi.org/10.3390/diagnostics11050796.

Full text
Abstract:
Background: Stroke (S), multiple sclerosis (MS), Parkinson’s disease (PD) are chronic neurological diseases that are a challange for public health and represent a real social problem. Physical activity (PA) improves functional performance, reduces various symptoms in PD and MS, in stroke- reduced neurological impairment of patients and provides a chance for independence. One of the main obstacles in successful rehabilitation is patients’ movement passivity. The reason might be the psychological aspects, in particular fear of movement—kinesiophobia. Aim: To determine how many patients with S, MS, and PD suffer from kinsiophobia and what factors influence this process. Methods: Fifty patients after stroke, eighty one MS patients and sixty one PD patients were consecutively recruited from hospital and outpatients clinics. The sociodemographic data, self- assesment of fitness, Visual Analogue Scale (VAS) for pain, Tampa Scale of Kinesiophobia (TSK) and The Modified Baecke Questionnarie for Older Adults for physical activity were collected. A score >37 was considered to indicate a high level of kinesiophobia according to the TSK. Results: High level of kinesiophobia was shown in 66.67% of the subjects. TSK medians in particular illnesses were above the cut-off score and amounted: S—42.50 points; MS—38 points; PD—42.00 points. Regression showed 15% of fluctuation of variance (R2 = 0.1498; p < 0.0001), where regression factor showed: for mobility self-assessment: b = −0.2137 and for the age b = 0.0065. Conclusions: Kinesiophobia among the patients suffering from S, MS and PD concerns most of the subjects. Predictors of kinesiophobia are: limitations connected with functioning and age. The meaning of kinesiophobia in neurological disorders requires further research.
APA, Harvard, Vancouver, ISO, and other styles
10

Jagaran, Keelan, and Moganavelli Singh. "Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s Diseases." International Journal of Molecular Sciences 22, no. 16 (August 23, 2021): 9082. http://dx.doi.org/10.3390/ijms22169082.

Full text
Abstract:
Neurodegenerative disorders involve the slow and gradual degeneration of axons and neurons in the central nervous system (CNS), resulting in abnormalities in cellular function and eventual cellular demise. Patients with these disorders succumb to the high medical costs and the disruption of their normal lives. Current therapeutics employed for treating these diseases are deemed palliative. Hence, a treatment strategy that targets the disease’s cause, not just the symptoms exhibited, is desired. The synergistic use of nanomedicine and gene therapy to effectively target the causative mutated gene/s in the CNS disease progression could provide the much-needed impetus in this battle against these diseases. This review focuses on Parkinson’s and Alzheimer’s diseases, the gene/s and proteins responsible for the damage and death of neurons, and the importance of nanomedicine as a potential treatment strategy. Multiple genes were identified in this regard, each presenting with various mutations. Hence, genome-wide sequencing is essential for specific treatment in patients. While a cure is yet to be achieved, genomic studies form the basis for creating a highly efficacious nanotherapeutic that can eradicate these dreaded diseases. Thus, nanomedicine can lead the way in helping millions of people worldwide to eventually lead a better life.
APA, Harvard, Vancouver, ISO, and other styles
11

Naija, S., I. Chatti, B. H. Manel, H. Anis, B. A. Sana, H. Salah, and B. A. Sofiene. "Parkinson'/INS;s disease and autonomic symptoms." Journal of the Neurological Sciences 333 (October 2013): e117. http://dx.doi.org/10.1016/j.jns.2013.07.393.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Conte, Carmela. "Possible Link between SARS-CoV-2 Infection and Parkinson’s Disease: The Role of Toll-Like Receptor 4." International Journal of Molecular Sciences 22, no. 13 (July 1, 2021): 7135. http://dx.doi.org/10.3390/ijms22137135.

Full text
Abstract:
Parkinson’s disease (PD) is the most common neurodegenerative motor disorder characterized by selective degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the midbrain, depletion of dopamine (DA), and impaired nigrostriatal pathway. The pathological hallmark of PD includes the aggregation and accumulation α-synuclein (α-SYN). Although the precise mechanisms underlying the pathogenesis of PD are still unknown, the activation of toll-like receptors (TLRs), mainly TLR4 and subsequent neuroinflammatory immune response, seem to play a significant role. Mounting evidence suggests that viral infection can concur with the precipitation of PD or parkinsonism. The recently identified coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of ongoing pandemic coronavirus disease 2019 (COVID-19), responsible for 160 million cases that led to the death of more than three million individuals worldwide. Studies have reported that many patients with COVID-19 display several neurological manifestations, including acute cerebrovascular diseases, conscious disturbance, and typical motor and non-motor symptoms accompanying PD. In this review, the neurotropic potential of SARS-CoV-2 and its possible involvement in the pathogenesis of PD are discussed. Specifically, the involvement of the TLR4 signaling pathway in mediating the virus entry, as well as the massive immune and inflammatory response in COVID-19 patients is explored. The binding of SARS-CoV-2 spike (S) protein to TLR4 and the possible interaction between SARS-CoV-2 and α-SYN as contributing factors to neuronal death are also considered.
APA, Harvard, Vancouver, ISO, and other styles
13

Szatmari, Szabolcs, Ben Min-Woo Illigens, Timo Siepmann, Alexandra Pinter, Annamaria Takats, and Daniel Bereczki. "Neuropsychiatric symptoms in untreated Parkinson’s disease." Neuropsychiatric Disease and Treatment Volume 13 (March 2017): 815–26. http://dx.doi.org/10.2147/ndt.s130997.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Abrantes, Ana M., Joseph H. Friedman, Richard A. Brown, David R. Strong, Julie Desaulniers, Eileen Ing, Jennifer Saritelli, and Deborah Riebe. "Physical Activity and Neuropsychiatric Symptoms of Parkinson Disease." Journal of Geriatric Psychiatry and Neurology 25, no. 3 (August 20, 2012): 138–45. http://dx.doi.org/10.1177/0891988712455237.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Calderón-Fajardo, Humberto, Amin Cervantes-Arriaga, Rodrigo Llorens-Arenas, Jesús Ramírez-Bermudez, Ángel Ruiz-Chow, and Mayela Rodríguez-Violante. "Electroconvulsive therapy in Parkinson´s disease." Arquivos de Neuro-Psiquiatria 73, no. 10 (September 1, 2015): 856–60. http://dx.doi.org/10.1590/0004-282x20150131.

Full text
Abstract:
Purpose To analyze the effectiveness of electroconvulsive therapy for the management of depression and/or psychosis refractory to drug therapy in patients with Parkinson disease.Methods A retrospective study was carried out including patients treated with electroconvulsive therapy during the period between 2002 and 2013. A review of the literature was performed.Results A total of 27 patients were included. In regards to the neuropsychiatric diagnosis, 14 patients had major depression, 12 patients had both psychosis and depression, and only one patient had isolated psychosis. The mean number of electroconvulsive therapy sessions was 12 ± 2.8. After electroconvulsive therapy, all patients showed a statistically significant improvement in the Brief Psychiatric Rating scale (reduction of 52% points) and Hamilton Depression Rating Scale (reduction of 50% points) independent of the presence of psychosis, depression or both.Conclusion Electroconvulsive therapy is effective for the treatment of refractory neuropsychiatric symptoms in Parkinson’s disease.
APA, Harvard, Vancouver, ISO, and other styles
16

Knezevic, Jelena, Vladimir Knezevic, Svetlana Simic, Lorand Sakalas, and Svetlana Ivanovic-Kovacevic. "Psychotic symptoms in Parkinson’s disease: Etiology, prevalence and treatment." Medical review 72, no. 1-2 (2019): 30–33. http://dx.doi.org/10.2298/mpns1902030k.

Full text
Abstract:
Introduction. Parkinson?s disease is the second most common neurodegenerative disease with as many as 50-70% of patients experiencing psychotic symptoms during the course of the illness. Our aim was to provide an evidence-based review on the etiology, prevalence and management of psychotic symptoms in Parkinson?s disease. Material and Methods. We used references from the ?Medline? database published from 1999 to 2019. Results. The most common psychotic symptoms in Parkinson?s disease are visual hallucinations, which occur in 25-30% of patients, acoustic hallucinations in about 20%, and delusions in around 5% of these patients. The etiology of psychotic symptoms is not fully clarified, but researchers suggest a complex interrelationship of factors associated with the disease itself and the factors associated with antiparkinsonian medications. After exclusion of other etiologic causes of psychotic symptoms, it is necessary to revise the type and dose of antiparkinsonian drugs. Although pimavanserin has recently been approved by the United States Food and Drug Administration, the current treatment of choice for psychotic symptoms in Parkinson?s disease is still quetiapine. Only patients who do not tolerate or do not respond to quetiapine are treated with clozapine, which has been proven more effective, but with significant side effects. Conclusion. Timely diagnosis and adequate treatment of psychotic symptoms in Parkinson?s disease are essential, because they dramatically affect the quality of life of patients and their families. Therefore, it is necessary to establish more effective tools for screening and treatment of psychotic symptoms in Parkinson?s disease.
APA, Harvard, Vancouver, ISO, and other styles
17

Junakovic, Alisa, and Srdjana Telarovic. "The effects of art therapy on Parkinson`s and Alzheimer`s disease." Medicina Fluminensis 57, no. 3 (September 1, 2021): 236–43. http://dx.doi.org/10.21860/medflum2021_261184.

Full text
Abstract:
Art therapy is one of the non-pharmacological treatment modalities for many diseases, including neurological and psychiatric disorders. Adrian Hill started art therapy in the 1940s. Parkinson`s disease is one of the progressive neurodegenerative diseases characterized by various motor and non-motor symptoms. As patients with Parkinson`s disease often report low quality of life despite improving their motor symptoms, complementary therapy may reduce their difficulties. Music and dance therapy, clay manipulation therapy, and tai chi training have promising results. There is also art therapy for one of the most common causes of dementia worldwide, Alzheimer`s disease. In addition to standard pharmacological treatment for Alzheimer`s disease e.g. cholinesterase inhibitors, music and visual arts therapy are evolving. This article presented some of the art therapy methods used in the most common neurodegenerative disorders, Parkinson`s and Alzheimer`s. In addition, we also presented some of the limitations of those studies. Some of the limitations are as follows: small sample size, relatively short duration of therapy sessions, and the fact that it is doubtful that art therapy could improve symptoms and cognitive abilities of people with advanced forms of neurodegenerative disorders.
APA, Harvard, Vancouver, ISO, and other styles
18

Glendinning, D., V. Patel, D. Maldonado, G. Siozon, and P. Trivedi. "SELF-REPORTED EARLIEST SYMPTOMS OF PARKINSON DISEASE." Journal of Neurologic Physical Therapy 29, no. 4 (December 2005): 208. http://dx.doi.org/10.1097/01.npt.0000282381.10560.33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Garber, C. E., and J. H. Friedman. "PHYSICAL ACTIVITY, FUNCTION AND FATIGUE IN PARKINSON??S DISEASE." Medicine & Science in Sports & Exercise 35, Supplement 1 (May 2003): S235. http://dx.doi.org/10.1097/00005768-200305001-01311.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Murakami, H., A. Sugimoto, A. Futamura, K. Fujita, Y. Saito, A. Kuriki, S. Ishigaki, et al. "Correlation between cognitive function and motor symptoms in Parkinson'/INS;s disease." Journal of the Neurological Sciences 333 (October 2013): e129. http://dx.doi.org/10.1016/j.jns.2013.07.430.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Criciotoiu, Oana, Diana Iulia Stanca, Daniela-Gabriela Glavan, Cecil Sorin Mirea, Adrian Mita, Veronica Calborean, Victor Gheorman, et al. "Statistical Analysis Between the Routes of Administration of L-Dopa and Digestive Dysfunctions in Parkinson Disease." Revista de Chimie 70, no. 4 (May 15, 2019): 1403–5. http://dx.doi.org/10.37358/rc.19.4.7137.

Full text
Abstract:
The aim of this study was to evaluate possible correlation between routes of administration of levodopa in patients diagnosed with Parkinson�s disease and the presence of digestive symptoms. We included in this study 31 patients diagnosed with Parkinson�s disease:14 patients were on oral levodopa and 17 patients were on intrajejunal administration of levodopa/carbidopa. Each patient was assessed using Non-motor Symptoms Questionnaire for Parkinson�s Disease regarding the dysfunction of gastrointestinal tract. The results of our study indicated that there is a different distribution of the digestive dysfunction between the two groups of patients. The study indicate that the constipation was more frequent in those patients with oral medication.
APA, Harvard, Vancouver, ISO, and other styles
22

Crizzle, Alexander Michael, and Ian J. Newhouse. "Is Physical Exercise Beneficial for Persons with Parkinson??s Disease?" Clinical Journal of Sport Medicine 16, no. 5 (September 2006): 422–25. http://dx.doi.org/10.1097/01.jsm.0000244612.55550.7d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Holanda, Victor A. D., Julia J. Didonet, Manara B. B. Costa, Adriano H. do Nascimento Rangel, Edilson D. da Silva, and Elaine C. Gavioli. "Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease." Pharmaceuticals 14, no. 8 (August 6, 2021): 775. http://dx.doi.org/10.3390/ph14080775.

Full text
Abstract:
Parkinson disease (PD) is a neurodegenerative disease mainly characterized by the loss of nigral dopaminergic neurons in the substantia nigra pars compacta. Patients suffering from PD develop severe motor dysfunctions and a myriad of non-motor symptoms. The treatment mainly consists of increasing central dopaminergic neurotransmission and alleviating motor symptoms, thus promoting severe side effects without modifying the disease’s progress. A growing body of evidence suggests a close relationship between neuropeptide S (NPS) and its receptor (NPSR) system in PD: (i) double immunofluorescence labeling studies showed that NPSR is expressed in the nigral tyrosine hydroxylase (TH)-positive neurons; (ii) central administration of NPS increases spontaneous locomotion in naïve rodents; (iii) central administration of NPS ameliorates motor and nonmotor dysfunctions in animal models of PD; (iv) microdialysis studies showed that NPS stimulates dopamine release in naïve and parkinsonian rodents; (v) central injection of NPS decreases oxidative damage to proteins and lipids in the rodent brain; and, (vi) 7 days of central administration of NPS protects from the progressive loss of nigral TH-positive cells in parkinsonian rats. Taken together, the NPS/NPSR system seems to be an emerging therapeutic strategy for alleviating motor and non-motor dysfunctions of PD and, possibly, for slowing disease progress.
APA, Harvard, Vancouver, ISO, and other styles
24

Safonova, N. Y. "Genetic aspects of non-motor symptoms in Parkinson’s disease." V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY, no. 4-1 (December 9, 2019): 86–87. http://dx.doi.org/10.31363/2313-7053-2019-4-1-86-87.

Full text
Abstract:
Non-motor symptoms are common in Parkinson`s disease and reflect the multisystem nature of the disorder. Parkinson’s disease is highly heterogeneous in early clinical features and later outcomes. This makes classifying genetic subgroups of PD relevant to clinical research and practice, particularly if they are prognostically relevant. Non-motor sypmptoms may be detrimental to patients’ functional status and sense of well-being.
APA, Harvard, Vancouver, ISO, and other styles
25

Gubanova, E., and N. Fedorova. "Non-motor symptoms in patients with early stages of Parkinson'/INS;s disease." Journal of the Neurological Sciences 333 (October 2013): e74. http://dx.doi.org/10.1016/j.jns.2013.07.534.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Balaz, M., and N. Zemanova. "Clinical profile of neuropsychiatric symptoms in parkinson´s disease in movement disorders center." Journal of the Neurological Sciences 381 (October 2017): 217. http://dx.doi.org/10.1016/j.jns.2017.08.620.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

De Luca, Vincenzo, Grazia Annesi, E. Valeria De Marco, Andrea de Bartolomeis, Giuseppe Nicoletti, Pierfrancesco Pugliese, Giovanni Muscettola, Paolo Barone, and Aldo Quattrone. "HOMER1 Promoter Analysis in Parkinson’s Disease: Association Study with Psychotic Symptoms." Neuropsychobiology 59, no. 4 (2009): 239–45. http://dx.doi.org/10.1159/000230689.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Rohde, K., M. Fauser, C. Ossig, S. Brown, A. Maaß, and A. Storch. "A psychoeducative group-intervention for depressive symptoms associated with Parkinson™s disease." Basal Ganglia 3, no. 1 (March 2013): 52. http://dx.doi.org/10.1016/j.baga.2013.01.036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Lan, Jianqiang, Zhongqiang Liu, Chenghong Liao, David J. Merkler, Qian Han, and Jianyong Li. "A Study for Therapeutic Treatment against Parkinson’s Disease via Chou’s 5-steps Rule." Current Topics in Medicinal Chemistry 19, no. 25 (November 29, 2019): 2318–33. http://dx.doi.org/10.2174/1568026619666191019111528.

Full text
Abstract:
The enzyme L-DOPA decarboxylase (DDC), also called aromatic-L-amino-acid decarboxylase, catalyzes the biosynthesis of dopamine, serotonin, and trace amines. Its deficiency or perturbations in expression result in severe motor dysfunction or a range of neurodegenerative and psychiatric disorders. A DDC substrate, L-DOPA, combined with an inhibitor of the enzyme is still the most effective treatment for symptoms of Parkinson&#039;s disease. In this review, we provide an update regarding the structures, functions, and inhibitors of DDC, particularly with regards to the treatment of Parkinson&#039;s disease. This information will provide insight into the pharmacological treatment of Parkinson&#039;s disease.
APA, Harvard, Vancouver, ISO, and other styles
30

Sakai, T., K. Tanaka, R. Shigematsu, M. Nakagaichi, M. Wada, and Y. Nakamura. "EXERCISES RECOMMENDED FOR PATIENTS WITH PARKINSON??S DISEASE." Medicine & Science in Sports & Exercise 33, no. 5 (May 2001): S321. http://dx.doi.org/10.1097/00005768-200105001-01796.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Hughes, Katherine C., Xiang Gao, Samantha Molsberry, Linda Valeri, Michael A. Schwarzschild, and Alberto Ascherio. "Physical activity and prodromal features of Parkinson disease." Neurology 93, no. 23 (November 12, 2019): e2157-e2169. http://dx.doi.org/10.1212/wnl.0000000000008567.

Full text
Abstract:
ObjectiveTo investigate the relationship between physical activity and prodromal features of Parkinson disease that often precede the clinical diagnosis.MethodsIncluded are participants in 2 well-established cohorts: the Nurses' Health Study and the Health Professionals Follow-up Study. Physical activity was assessed using validated questionnaires at baseline (1986) and every 2 years until 2008. Prodromal features (e.g., constipation, hyposmia, and probable REM sleep behavior disorder [pRBD]) were assessed in 2012–2014.ResultsThe multivariable-adjusted odds ratio (OR) for having ≥3 prodromal features vs none comparing the highest to the lowest quintile were 0.65 (95% confidence interval [CI] 0.53–0.79; ptrend = 0.0006) for baseline physical activity and 0.52 (95% CI 0.35–0.76; ptrend = 0.009) for cumulative average physical activity. Considering each feature independently, baseline physical activity was associated with lower odds of constipation (OR 0.78, 95% CI 0.73–0.83; ptrend < 0.0001), excessive daytime sleepiness (OR 0.72, 95% CI 0.60–0.86; ptrend = 0.002), depressive symptoms (OR 0.82, 95% CI 0.69–0.97; ptrend = 0.13), and bodily pain (OR 0.81, 95% CI 0.68–0.96; ptrend = 0.03). Similar or stronger associations were observed for cumulative average physical activity, which, in addition, was associated with pRBD (OR 0.85, 95% CI 0.77–0.95; ptrend = 0.02). In contrast, neither hyposmia nor impaired color vision was associated with physical activity. Early life physical activity was associated with constipation and, in men only, with the co-occurrence of ≥3 features.ConclusionsThe reduced prevalence of prodromal features associated with Parkinson disease in older individuals who were more physically active in midlife and beyond is consistent with the hypothesis that high levels of physical activity may reduce risk of Parkinson disease.
APA, Harvard, Vancouver, ISO, and other styles
32

Cevik, Feyza, and Zeynep Hilal Kilimci. "Analysis of Parkinson’s Disease using Deep Learning and Word Embedding Models." Academic Perspective Procedia 2, no. 3 (November 22, 2019): 786–97. http://dx.doi.org/10.33793/acperpro.02.03.86.

Full text
Abstract:
Parkinson&apos;s disease is a common neurodegenerative neurological disorder, which affects the patient&apos;s quality of life, has significant social and economic effects, and is difficult to diagnose early due to the gradual appearance of symptoms. Examining the discussion of Parkinson&amp;rsquo;s disease in social media platforms such as Twitter provides a platform where patients communicate each other in both diagnosis and treatment stage of the Parkinson&amp;rsquo;s disease. The purpose of this work is to evaluate and compare the sentiment analysis of people about Parkinson&apos;s disease by using deep learning and word embedding models. To the best of our knowledge, this is the very first study to analyze Parkinson&apos;s disease from social media by using word embedding models and deep learning algorithms. In this study, Word2Vec, GloVe, and FastText are employed as word embedding models for the purpose of enriching tweets in terms of semantic, context, and syntax. Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), and Long Short-Term Memory Networks (LSTMs) are implemented for the classification task. This study demonstrates the efficiency of using word embedding models and deep learning algorithms to understand the needs of patients&amp;rsquo; and provide a valuable contribution to the treatment process by analyzing sentiments of them with 93.63% accuracy performance.
APA, Harvard, Vancouver, ISO, and other styles
33

Marvanova, Marketa. "Introduction to Parkinson disease (PD) and its complications." Mental Health Clinician 6, no. 5 (September 1, 2016): 229–35. http://dx.doi.org/10.9740/mhc.2016.09.229.

Full text
Abstract:
Abstract Parkinson disease (PD) is a common neurodegenerative disorder in older adults characterized by motor and nonmotor symptoms and complications. Impulse control disorders (ICDs), such as pathological gambling, compulsive shopping, compulsive sexual behavior (hypersexuality), and binge eating disorder, affect 13.6% of the PD population. Use of dopamine receptor agonists (DRAs) is considered a major risk factor for ICD development. Amantadine and a high dose of levodopa were linked to ICDs to a lesser extent than DRAs. Based on the severity of behavior(s), ICDs can negatively impact social, professional, and familial lives of patients and their families. Ideally, all PD patients taking DRAs, high doses of levodopa, and/or amantadine should be routinely asked about or monitored for ICDs during therapy initiation and continuation. Dose decrease or withdrawal of the offending agent, primarily DRAs, is usually the most effective first step in ICD management. Careful dose adjustment with close monitoring is warranted due to risk for worsening of motor symptoms or emergence of dopamine agonist withdrawal syndrome (DAWS). About 1/3 of PD patients with ICD who decrease or discontinue DRA experienced DAWS. The lowest dose of DRA will need to be continued to balance ICDs and DAWS as it is not alleviated by other dopaminergic or psychotropic medications. Other therapies with low empiric evidence, such as amantadine, naloxone, cognitive behavior therapy, deep brain stimulation, and psychopharmacotherapy showed mixed results for ICD management. It is crucial that clinicians are familiar with the psychiatric complications of PD, including ICDs, beyond mere recognition and management of motor symptoms.
APA, Harvard, Vancouver, ISO, and other styles
34

Uc, Ergun Y., Jon Tippin, Kelvin L. Chou, Bradley A. Erickson, Kevin C. Doerschug, and Decontee M. Jimmeh Fletcher. "Non-motor Symptoms in Parkinson’s Disease." US Neurology 07, no. 02 (2011): 113. http://dx.doi.org/10.17925/usn.2011.07.02.113.

Full text
Abstract:
In addition to typical motor dysfunction (parkinsonism), diverse non-motor symptoms (NMS) are frequently observed in patients with Parkinson’s disease (PD). Some NMS may antedate the diagnosis of PD. Examples of NMS include cognitive impairment, autonomic dysfunction, visual dysfunction, sleep abnormalities, and psychiatric disorders. NMS are associated with wide-ranging abnormalities in extranigral dopaminergic systems and non-dopaminergic (e.g. cholinergic, noradrenergic, serotoninergic) systems. The type and severity of NMS vary based on age, disease severity, and predominant motor symptoms. NMS can be disabling and reduce quality of life. Treatment of NMS can be challenging. Some NMS are helped by dopaminergic treatment, whereas others can be induced or exacerbated by treatments that help the motor dysfunction. Physicians should probe their PD patients about their NMS and address them for better care. Clinical trials should incorporate NMS as outcomes for more meaningful conclusions on the effect of treatments under investigation.
APA, Harvard, Vancouver, ISO, and other styles
35

Skogar, Orjan, and Mats Nilsson. "Distribution of non-motor symptoms in idiopathic Parkinson’s disease and secondary Parkinsonism." Journal of Multidisciplinary Healthcare Volume 11 (October 2018): 525–34. http://dx.doi.org/10.2147/jmdh.s170307.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Picillo, M., M. Amboni, R. Erro, M. Moccia, C. Vitale, G. De Michele, A. De Rosa, et al. "Gender differences in non-motor symptoms in early, drug naïve Parkinson'/INS;s disease." Journal of the Neurological Sciences 333 (October 2013): e145. http://dx.doi.org/10.1016/j.jns.2013.07.482.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Magerkurth, Christiane, Rita Schnitzer, and Stefan Braune. "Symptoms of autonomic failure in Parkinson?s disease: prevalence and impact on daily life." Clinical Autonomic Research 15, no. 2 (April 2005): 76–82. http://dx.doi.org/10.1007/s10286-005-0253-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

REUTER, IRIS, MARTIN ENGELHARDT, KLAUS STECKER, and HORST BAAS. "Therapeutic value of exercise training in Parkinson???s disease." Medicine & Science in Sports & Exercise 31, no. 11 (November 1999): 1544. http://dx.doi.org/10.1097/00005768-199911000-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Snyder, Charlene Hoffman, and Charles H. Adler. "The patient with Parkinson?s disease: Part I?Treating the motor symptoms; Part II?Treating the nonmotor symptoms." Journal of the American Academy of Nurse Practitioners 19, no. 4 (April 2007): 179–97. http://dx.doi.org/10.1111/j.1745-7599.2007.00211.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Pellecchia, M. T., A. Grasso, L. G. Biancardi, M. Squillante, V. Bonavita, and P. Barone. "Physical therapy in Parkinson?s disease: an open long-term rehabilitation trial." Journal of Neurology 251, no. 5 (May 1, 2004): 595–98. http://dx.doi.org/10.1007/s00415-004-0379-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Mott, Sarah, Marita Kenrick, Miriam Dixon, and Graham Bird. "Only misunderstood? The effects of Parkinson's Disease on interactions with health professionals." Australian Journal of Primary Health 10, no. 2 (2004): 82. http://dx.doi.org/10.1071/py04030.

Full text
Abstract:
Many people living with Parkinson?s disease (PWP) experience a variety of voice and swallowing difficulties as well as spontaneous movement and facial expression deficiencies. Impaired communication affects the ways in which people engage with others in a variety of settings. This paper reports on a study undertaken in New South Wales to ascertain the support needs of people with Parkinson?s disease. Responses to a 31-item survey were received from 444 people with the disease. Sixty-four per cent (n=243) reported experiencing difficulties with communication. These difficulties were compounded by participants? perceptions of a lack of understanding by health professionals about what it is like to live with this disease. The findings increase our understanding of the potential difficulties encountered by people living with Parkinson?s disease. They provide evidence of the need for health professionals to be especially sensitive to this client group in the provision of adequate time and expertise for the effective identification and management of symptoms.
APA, Harvard, Vancouver, ISO, and other styles
42

Brognara, Lorenzo, and Omar Cauli. "Mechanical Plantar Foot Stimulation in Parkinson′s Disease: A Scoping Review." Diseases 8, no. 2 (May 10, 2020): 12. http://dx.doi.org/10.3390/diseases8020012.

Full text
Abstract:
Background: Parkinson′s disease (PD) is the second most prevalent neurodegenerative disease in older individuals. Neurorehabilitation-based interventions such as those improving gait are crucial for a holistic approach and to limit falls. Several studies have recently shown that mechanical plantar foot stimulation is a beneficial intervention for improving gait impairment in PD patients. The objective of this scoping review is to evaluate the beneficial effects of this stimulation on gait parameters, and to analyse protocols of foot stimulation and other effects in non-motor symptoms. Relevant articles were searched in the Medline database using Pubmed and Scopus, using the primary search terms ‘foot stimulation’ OR ‘plantar stimulation’ AND ‘Parkinson’s disease*’. Several protocols have been used for mechanical plantar foot stimulation (ranging from medical devices to textured insoles). The gait parameters that have been shown to be improved are stride length and walking speed. The beneficial effects are achieved after both acute and repeated plantar foot stimulation. Beneficial effects are observed in other organs and systems, such as muscle activation, brain connectivity, cardiovascular control in the central nervous system, and the release of brain-derived neurotrophic factor and cortisol in blood added evidence about this intervention’s impact on brain function. Mechanical plantar foot stimulation is a safe and effective add-on treatment able for improving gait impairments in PD patients during the L-dopa off state. Randomized and controlled clinical trials to study its eventual potentiating effect with different pharmacotherapy regimens are warranted.
APA, Harvard, Vancouver, ISO, and other styles
43

Snider, Jonathan, Martijn L. T. M. Müller, Vikas Kotagal, Robert A. Koeppe, Peter J. H. Scott, Kirk A. Frey, Roger L. Albin, and Nicolaas I. Bohnen. "Non-exercise physical activity attenuates motor symptoms in Parkinson disease independent from nigrostriatal degeneration." Parkinsonism & Related Disorders 21, no. 10 (October 2015): 1227–31. http://dx.doi.org/10.1016/j.parkreldis.2015.08.027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Freo, Ulderico, Maurizio Furnari, and Carlo Ori. "Effects of tapentadol on pain, motor symptoms and cognitive functions in Parkinson’s disease." Journal of Pain Research Volume 11 (September 2018): 1849–56. http://dx.doi.org/10.2147/jpr.s164939.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Isaacson, Stuart H. "Parkinson’s Disease Psychosis—A Symptom Complex Signaling Risk for Increased Disability and Caregiver Burden." US Neurology 11, no. 01 (2015): 23. http://dx.doi.org/10.17925/usn.2015.11.01.23.

Full text
Abstract:
Parkinson’s disease psychosis (PDP) occurs frequently in patients with Parkinson’s disease (PD) and involves a spectrum of symptoms, from mild hallucinations to those that are more disruptive, as well as delusions, particularly around spousal infidelity and theft of money or possessions. Risk factors for PDP include dopaminergic (and other) medications, cognitive disorders, sleep disorders, and duration of PD. Emerging evidence suggests that PDP also reflects underlying PD pathology. Routine querying of major PDP symptoms can hasten recognition and allow earlier diagnosis of PDP. Mild hallucinations with retained insight are frequent and may be tolerable by patients and caregivers, but symptoms that can be considered as psychosis will typically increase in frequency and severity. Increasing PDP results in patient distress, increased caregiver burden, and is a leading cause of long-term nursing home placement. PDP has also been associated with an increased risk for morbidity and mortality. Ongoing research into the prevalence, risk factors, phenomenology, pathophysiology, and emerging pharmacotherapy for PDP provides hope for improved diagnosis and management of PDP.
APA, Harvard, Vancouver, ISO, and other styles
46

Doręgowska, Magdalena, and Monika Rudzińska-Bar. "SLEEP DISORDERS IN PARKINSON’S DISEASE." Wiadomości Lekarskie 72, no. 3 (2019): 425–31. http://dx.doi.org/10.36740/wlek201903120.

Full text
Abstract:
Sleep disorder are common non-motor symptoms in Parkinson`s disease (PD). They can be found in different sleep stages or appear during the daytime. They correlate with faster progression of motor problems and lower quality of a patient’s life. Sleep physiology, different sleep dysfunction such as: RBD-REM sleep behavior disorder, EDS – excessive daytime sleepiness, insomnia, OSAS-obstructive sleep apnea syndrome, and their clinical manifestation have been presented in this review. Diagnostic and therapy possibilities have been summarized as well. Particular attention has also been paid to the coexistence of various non-motor symptoms such as pain, depression or nocturia, and their correlations with sleeping problems.
APA, Harvard, Vancouver, ISO, and other styles
47

Otte, Karen, Tobias Ellermeyer, Tim-Sebastian Vater, Marlen Voigt, Daniel Kroneberg, Ludwig Rasche, Theresa Krüger, et al. "Instrumental Assessment of Stepping in Place Captures Clinically Relevant Motor Symptoms of Parkinson’s Disease." Sensors 20, no. 19 (September 23, 2020): 5465. http://dx.doi.org/10.3390/s20195465.

Full text
Abstract:
Fluctuations of motor symptoms make clinical assessment in Parkinson’s disease a complex task. New technologies aim to quantify motor symptoms, and their remote application holds potential for a closer monitoring of treatment effects. The focus of this study was to explore the potential of a stepping in place task using RGB-Depth (RGBD) camera technology to assess motor symptoms of people with Parkinson’s disease. In total, 25 persons performed a 40 s stepping in place task in front of a single RGBD camera (Kinect for Xbox One) in up to two different therapeutic states. Eight kinematic parameters were derived from knee movements to describe features of hypokinesia, asymmetry, and arrhythmicity of stepping. To explore their potential clinical utility, these parameters were analyzed for their Spearman’s Rho rank correlation to clinical ratings, and for intraindividual changes between treatment conditions using standard response mean and paired t-test. Test performance not only differed between ON and OFF treatment conditions, but showed moderate correlations to clinical ratings, specifically ratings of postural instability (pull test). Furthermore, the test elicited freezing in some subjects. Results suggest that this single standardized motor task is a promising candidate to assess an array of relevant motor symptoms of Parkinson’s disease. The simple technical test setup would allow future use by patients themselves.
APA, Harvard, Vancouver, ISO, and other styles
48

Hass, C. J., D. E. Waddell, D. W. Smith, J. L. Juncos, S. L. Wolf, and R. J. Gregor. "PARKINSON??S DISEASE AFFECTS LOWER EXTREMITY JOINT MOMENTS DURING GAIT." Medicine & Science in Sports & Exercise 35, Supplement 1 (May 2003): S128. http://dx.doi.org/10.1097/00005768-200305001-00705.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Tarianyk, Kateryna A., Nataliya V. Lytvynenko, Anastasiia D. Shkodina, and Igor P. Kaidashev. "THE ROLE OF CIRCADIAN REGULATION OF GHRELIN LEVELS IN PARKINSON’S DISEASE (LITERATURE REVIEW)." Wiadomości Lekarskie 74, no. 7 (2021): 1750–53. http://dx.doi.org/10.36740/wlek202107132.

Full text
Abstract:
The paper is aimed at the analysis of the role of the circadian regulation of ghrelin levels in patients with Parkinson’s disease. Based on the literature data, patients with Parkinson’s disease have clinical fluctuations in the symptoms of the disease, manifested by the diurnal changes in motor activity, autonomic functions, sleep-wake cycle, visual function, and the efficacy of dopaminergic therapy. Biological rhythms are controlled by central and peripheral oscillators which links with dopaminergic neurotransmission – core of the pathogenesis of Parkinson`s disease. Circadian system is altered in Parkinson`s disease due to that ghrelin fluctuations may be changed. Ghrelin is potential food-entrainable oscillator because it is linked with clock genes expression. In Parkinson`s disease this hormone may induce eating behavior changing and as a result metabolic disorder. The “hunger hormone” ghrelin can be a biomarker of the Parkinson’s disease, and the study of its role in the pathogenesis, as well as its dependence on the period of the day, intake of levodopa medications to improve the effectiveness of treatment is promising.
APA, Harvard, Vancouver, ISO, and other styles
50

Singh, Gurpreet, Tarang K. Jain, Wen Liu, Yvonne Colgrove, Rajesh Pahwa, Kelly Lyon, and Neena Sharma. "Effects of Balance Training on Nonmotor Symptoms in Individuals With Parkinson Disease." Topics in Geriatric Rehabilitation 36, no. 3 (July 2020): 187–93. http://dx.doi.org/10.1097/tgr.0000000000000279.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography